Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capivasertib is an oral kinase inhibitor that targets all three isoforms of the AKT enzyme (AKT1, AKT2, and AKT3).How Effective is Capivasertib?The CAPItello-291 study is a phase Ⅲ···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：215
Drugs used to treat cancer are usually highly potent and may cause numerous side effects. Before using this medication, ensure that you understand all its risks and benefits. It is···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：221
Capivasertib (trade name: Truqap) is the world’s first approved AKT protein kinase inhibitor. Combined with fulvestrant, it is indicated for the treatment of hormone receptor-posit···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：148
Capivasertib in combination with fulvestrant can be used as a second-line or third-line treatment regimen for patients with metastatic breast cancer who are hormone receptor-positi···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：122
Capivasertib in combination with Faslodex is indicated for the treatment of adult patients with a specific type of hormone receptor-positive (hormone-dependent, e.g., estrogen-depe···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：165
Capivasertib, in combination with Fulvestrant, is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced o···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：152
Capivasertib belongs to a class of medications known as antineoplastic agents. It interferes with the growth of cancer cells and ultimately leads to their destruction.Latest Price ···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：177
On November 17, 2023, AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) was approved in the United States for the treatment of adult patients with hormone recep···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：185
On June 12, 2023, the New Drug Application (NDA) for capivasertib in combination with fulvestrant, submitted by AstraZeneca, has been accepted for review and granted priority revie···【more】
Article source：Captain MedicineRelease date：2026-01-13Recommended：157
Capmatinib slows down or inhibits the spread of cancer cells by blocking a key protein that promotes the growth and proliferation of cancer cells.Which drugs interact with Capmatin···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：158
The mechanism of action of capmatinib lies in targeting and blocking the specific proteins that drive the growth and proliferation of cancer cells, thereby inhibiting cancer progre···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：169
Camatinib is indicated for the treatment of specific types of non-small cell lung cancer that has spread to other parts of the body. Belonging to the class of kinase inhibitors, ca···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：175
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6382024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：952026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4162025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4402025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4802025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3882025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
